IN8bio, a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for cancer and autoimmune diseases, has announced that The Ohio State University has joined as a new clinical site in its ongoing Phase 1 trial of INB-100. The donor-derived allogeneic gamma-delta T cell therapy is designed for patients with leukemias undergoing haploidentical stem cell transplantation.
The addition of The Ohio State University marks a significant milestone for the INB-100 program, reflecting the growing momentum of interest from leading academic institutions. The expansion aims to accelerate patient enrollment and advance completion of the Phase 1 study, which is evaluating the safety, durability, and anti-leukemic activity of IN8bio’s allogeneic gamma-delta T cell therapy in the post-transplant setting.
The trial, led by Principal Investigator Dr. Joseph P. McGuirk, the Schutte-Speas Professor of Hematology-Oncology and Medical Director of Blood and Marrow Transplant at the Kansas University Cancer Center, has already shown encouraging clinical data. These include strong long-term survival outcomes compared to real-world historical data, durable immune reconstitution with the persistence of INB-100 gamma-delta T cells for up to one year post-treatment, and the absence of severe graft-versus-host disease.
With multiple clinical sites now screening patients, IN8bio anticipates completing enrollment of the expansion cohort and sharing follow-up data next year. Early results suggest that INB-100 has the potential to improve post-transplant outcomes and reduce relapse in patients with complex, high-risk leukemia. The earliest treated participants have now surpassed four to five years of relapse-free survival.
KEY QUOTES:
“This trial is an excellent opportunity to explore a strategy aimed at reducing the risk of graft-versus-host disease and the risk of relapse following haploidentical stem cell transplant. The increased use of haploidentical donors in the last decade has created more access to potentially life-saving allogeneic transplants for many patients, particularly under-represented groups who are less likely to have fully matched donors. I am incredibly excited to be opening and leading this trial at The James Comprehensive Cancer Center at Ohio State University.”
Sarah A. Wall, M.D., Investigator and Assistant Professor, College of Medicine, The Ohio State University
“We are excited to welcome The Ohio State University as a clinical partner in the INB-100 study. With multiple sites actively screening, we look forward to completing the enrollment of the expansion cohort and providing follow-up data next year. INB-100 continues to demonstrate the potential of gamma-delta T cells to improve outcomes and reduce relapse in patients following stem cell transplantation. Multiple patients with complex, high-risk disease continue to demonstrate long-term leukemic remissions with the earliest treated patients now beyond four- and five-years relapse-free.”
William Ho, CEO and Co-Founder, IN8bio
